Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma
Status:
Unknown status
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Randomized phase II study designed to evaluate the efficacy and safety of continuous S-1 plus
oxaliplatin versus intermittent S-1 plus oxaliplatin as first-line therapy in patients with
recurrent and/or metastastic gastric carcinoma. Within 2 weeks of the end of induction
chemotherapy of 6 cycles with S-1 plus oxalipatin, patients who don't experience progression
will be randomized to the continuous S-1 plus oxaliplatin arm or the intermittent S-1 plus
oxaliplatin arm in a 1:1 ratio.